The Food and Drug Administration acted after preliminary results from a government-sponsored study showed that Gilead Sciences' remdesivir shortened the time to recovery by 31%, or about four days on average, for hospitalized COVID-19 patients.
from Section Page News - Modern Healthcare https://ift.tt/2VRFvK6
via IFTTT
Get access to the Ultimate Professional Medical Tourism Agent Online Course
No comments:
Post a Comment